Moderna's COVID-19 Vaccine Scores Canadian Approval For Kids Below 5 Years

  • Health Canada has approved the use of Moderna Inc's MRNA mRNA COVID-19 vaccine, Spikevax, in a two-dose series of 25 µg per dose in children six months to 5 years. 
  • Positive interim results from the Phase 2/3 KidCOVE study, announced in March, showed a robust neutralizing antibody response in the 6-month to 5 years of age group. 
  • The antibody titers in the pre-specified six-month to 23-month and two to 5 years of age sub-groups met the statistical criteria. 
  • Related: Moderna's Bivalent COVID-19 Booster Shows Antibody Response Against Omicron Subvariants.
  • Preliminary efficacy analysis during the Omicron wave showed similar efficacy estimates against Omicron in the 6-month to 5 years.
  • European Medicines Agency added extensive swelling of the vaccinated limb in the EU product information as a side effect of Spikevax.
  • Price Action: MRNA shares are down 7.18% at $158.91 during the market session on the last check Thursday.
  • Photo by mufidpwt via Pixabay
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLarge CapNewsHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!